PL
Peter Llewellyn-Davies
Chief Executive Officer & Chief Financial Officer
invIOsinvIOs Pipeline
| Drug | Indication | Phase |
|---|
| INV441 | Glioblastoma Multiforme | Pre-clinical |
| APN401 | Advanced Solid Tumors | Phase 1 |
| INV451 | Solid Tumors (CAR enhancer) | Pre-clinical |
| INV461 | Acute Myeloid Leukemia (AML) | Discovery |
| INV501 | Undisclosed (Immune activation) | Pre-clinical |